格隆汇1月4日丨海正药业(600267.SH)公布，持股5%以上股东浙江省国际贸易集团有限公司（简称"国贸 集团"）拟通过公开征集转让的方式协议转让其直接持有的全部公司股份72,673,907股，约占公司总股本 的6.06%，股份性质全部为无限售条件流通股。若本次公开征集转让实施完成，国贸集团将不再直接持 有公司股份。 ...

Group 1 - Zhongmin Resources has completed the construction of a 30,000-ton high-purity lithium salt project, which began trial production on January 2, 2026, with a total investment of 121 million yuan [2] - Shaoyang Hydraulic's acquisition of 100% of Chongqing Xincheng Hangrui Technology has been accepted by the Shenzhen Stock Exchange [3] - Xingqi Eye Medicine received approval for the supplementary application of atropine sulfate eye drops, aimed at delaying myopia progression in children aged 6 to 12 [4] Group 2 - Bailong Oriental expects a net profit of 600 million to 700 million yuan for 2025, representing a year-on-year increase of 46.34% to 70.73% [5] - Magmite's application for a private placement has been approved by the China Securities Regulatory Commission [6] - *ST Aowei's stock may face delisting risk due to a market capitalization below 500 million yuan [7] Group 3 - Changyuan Power plans to invest 572 million yuan in a wind power project in Hubei Province, with a planned capacity of 100 MW [8] - Haizheng Pharmaceutical's shareholder intends to transfer 6.06% of the company's shares [9] - Fusheng Technology has received approval for a share issuance to acquire assets and raise matching funds [10] Group 4 - Tenglong Co. plans to establish a joint venture for a liquid cooling company with an investment of 30 million yuan [11] - *ST Tianshan reported sales of live livestock amounting to 24.6 million yuan in December 2025, with significant year-on-year growth [12] - Hengxin Oriental's controlling shareholder has released a pledge of 0.91% of shares [13] Group 5 - Peking University Pharmaceutical plans to distribute a cash dividend of 1.68 yuan per 10 shares, totaling 100 million yuan [14] - Tianlong Co. intends to acquire a 54.87% stake in Suzhou Haomi Bo for 232 million yuan [15] - Jinggong Technology's first carbon fiber production line has successfully commenced trial production [16] Group 6 - Shanfeng Cement has terminated its investment and asset acquisition plans due to disagreements on asset valuation [17] - Shengyang Co. plans to acquire 51% of Shenzhen Daren High-tech for approximately 74.47 million yuan [18] - Xinxiang Chemical has resumed production of biomass cellulose filament after equipment upgrades [19] Group 7 - Jiuding New Materials plans to invest 246 million yuan in a wind turbine blade production line project [20] - Hunan Baiyin's shareholder has reduced its stake to below 5% [21] - Century Huatong intends to repurchase shares worth 300 million to 600 million yuan [22] Group 8 - Jincai Hulin plans to acquire 51% of Wuxi Sanli for 63.43 million yuan [23] - Jiamei Packaging's stock has experienced abnormal trading fluctuations, but no significant undisclosed information has been found [25] - Guoguang Electric's general manager has resumed duties after the lifting of restrictions [26] Group 9 - Shengxing Co. is planning a private placement for 2025, with no significant changes in its operational situation [27] - *ST Meigu has applied to lift the delisting risk warning after completing its restructuring plan [28] - CATL has repurchased 15.99 million A-shares for a total of 4.386 billion yuan [29] Group 10 - Phoenix Shipping's actual controller has been released from mandatory measures [30] - Guoxin Technology's new neural network processor has successfully passed internal testing [31] - Yanjing Co. plans to acquire control of Ningbo Yongqiang Technology, leading to a stock suspension [32]

北京商报讯（记者 丁宁）1月4日晚间，海正药业（600267）发布公告称，公司持股5%以上股东浙江省 国际贸易集团有限公司（以下简称"国贸集团"）拟通过公开征集转让的方式协议转让其直接持有的全部 公司股份7267.39万股，约占公司总股本的6.06%，股份性质全部为无限售条件流通股。若本次公开征集 转让实施完成，国贸集团将不再直接持有公司股份。 ...

格隆汇1月4日丨海正药业(600267.SH)公布，截至2025年12月月底，公司已累计回购股份721.61万股，占 公司总股本的比例为0.60%，购买的最高价为10.55元/股、最低价为8.92元/股，已支付的总金额为 67,992,848.98元(不含交易费用)。 ...

关于持股 5%以上股东拟通过公开征集转让方式协议 转让公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600267 证券简称：海正药业 公告编号：临 2026-02 号 浙江海正药业股份有限公司 重要内容提示： 根据《上市公司国有股权监督管理办法》等相关规定，本次公开征集转让的 价格将不低于本次公开征集转让提示性公告日（2026年1月5日）前30个交易日的 浙江海正药业股份有限公司董事会 二○二六年一月五日 每日加权平均价格的算术平均值及最近一个会计年度公司经审计的每股净资产 值两者之中的较高者。最终转让价格将依据相关法律法规，以公开征集并经国有 资产监督管理部门等有权机构批复的结果确定。在本次公开征集转让完成前，如 果公司发生派息、送股、转增股本、配股等除权、除息事项，则转让股份的价格 和数量相应调整。 本次公开征集转让尚需取得国有资产监督管理部门等有权机构的批准，由国 有资产监督管理部门审批后方可进入公开征集转让程序。因此，本次公开征集转 让的实施能否取得国有资产管理部门等有权机构的批准及批 ...

证券代码：600267 证券简称：海正药业 公告编号：临 2026-01 号 浙江海正药业股份有限公司 重要内容提示： | 回购方案首次披露日 | 2025/5/13 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 5 5 | 12 | 日~2026 | 年 | 月 | 日 11 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 7,216,100股 | | | | | | | 累计已回购股数占总股本比例 | 0.60% | | | | | | | 累计已回购金额 | 67,992,848.98元 | | | | | | | 实际回购价格区间 | 8.92元/股~10.55元/股 | | | | | | 一、 回购股份的基本情况 关于第四次以集中竞价交易方式回购公司股份的进展 公 ...

Core Insights - The collaboration between Insilico Medicine and Haizheng Pharmaceutical has achieved a significant milestone by nominating a preclinical candidate compound (PCC) within approximately 8 months of their strategic partnership [1][2][3] Group 1: Collaboration Details - The partnership began in April 2025, focusing on innovative drug development through the integration of AI technology and traditional drug discovery methods [1] - Insilico Medicine is responsible for early-stage research, including target identification, lead compound discovery, and preclinical studies, while Haizheng Pharmaceutical will handle the clinical trial application and subsequent clinical trial processes [1][2] Group 2: Project Progress and Impact - Within the 8-month collaboration, Insilico Medicine efficiently advanced the early research and completed the necessary preclinical studies, meeting the PCC nomination standards set by both companies [2] - The project highlights the potential of AI-driven innovation in drug development, particularly in addressing unmet clinical needs in novel target areas [2][3] Group 3: Strategic Implications - The successful nomination of the PCC within a short timeframe validates the delivery capabilities of Insilico Medicine and the collaborative efficiency of both companies [3] - This collaboration serves as a representative case for local enterprises exploring new pathways in drug development through the synergy of AI platforms and pharmaceutical industrialization capabilities [3]

Group 1 - The collaboration between Insilico Medicine and Haizheng Pharmaceutical has achieved a milestone by nominating a preclinical candidate compound (PCC) within approximately 8 months of their strategic partnership [1][2] - The partnership began in April 2025, focusing on deep collaboration in drug discovery and development by integrating AI technology with traditional drug development advantages [1] - Insilico Medicine is responsible for early-stage research, including target identification, lead compound discovery, and preclinical studies, while Haizheng Pharmaceutical will handle clinical trial application support and subsequent clinical trial implementation [1] Group 2 - Insilico Medicine's Pharma.AI platform has efficiently advanced early-stage research, producing preclinical data that meets the PCC nomination standards set by both companies [2] - The rapid achievement of the PCC nomination demonstrates the potential of AI-driven innovation in early drug development, particularly in addressing unmet clinical needs [2][3] - Haizheng Pharmaceutical expressed strong impressions regarding the efficiency and quality of the project, highlighting the integration of traditional pharmaceutical experience with cutting-edge AI technology as a key step in their digital transformation [3]

浙江海正药业股份有限公司 2026 年第一次临时股东会会议资料 浙江海正药业股份有限公司 2026 年第一次临时股东会会议资料 二○二六年一月五日 浙江海正药业股份有限公司 2026 年第一次临时股东会会议资料 会议议程 六、宣布表决结果 三、股东及其授权代表发言及答疑 四、对上述各议案进行投票表决 五、统计有效表决票 时间：2026 年 1 月 5 日（周一）14:00，会期半天 地点：浙江海正药业股份有限公司（以下简称"公司"或"海正药业"）会议室（台州市 椒江区外沙路 46 号） 主要议程： 一、宣布会议开始并宣布到会代表资格审查结果 二、审议下列议案 | 序号 | 议案名称 | | --- | --- | | 非累积投票议案 | | | 1 | 关于签署转让全资子公司浙江省医药工业有限公司 100%股权相关合同的 | | 议案 | | 上述议案已经公司第十届董事会第十一次会议审议通过，具体内容详见 2025 年 12 月 18 日的《中国证券报》《上海证券报》《证券时报》及上海证券交易所网站 （www.sse.com.cn）。 一、本次会议设秘书处，处理会议的各项事务。 二、与会股东应自觉遵守会议纪律 ...

证券代码：600267 证券简称：海正药业 公告编号：临2025-84号 浙江海正药业股份有限公司 (四)现场会议召开的日期、时间和地点 关于召开2026年第一次临时股东会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江海正药业股份有限公司（以下简称"公司"）于2025年12月18日在《中 国证券报》《上海证券报》《证券时报》和上海证券交易所网站（www.sse.com.cn） 上刊登了《浙江海正药业股份有限公司关于召开2026年第一次临时股东会的通知》 （公告编号：临2025-79号）。本次股东会采用现场和网络投票相结合的方式召 开，现发布本次临时股东会提示性公告。 一、 召开会议的基本情况 (一)股东会类型和届次 2026年第一次临时股东会 召开的日期时间：2026 年 1 月 5 日 14 点 00 分 召开地点：浙江海正药业股份有限公司会议室（台州市椒江区外沙路 46 号） 股东会召开日期：2026年1月5日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二)股东会 ...